

EXHIBIT G

Plaintiffs' Preliminary List of Custodians for ZHP and Its Subsidiaries as of 11/25/2019						
First name	Last name	Title	Department	Co.	Proffered by	Explanation
Senior Management						
Jun	Du	Vice President of ZHP, CEO of Huahai US, Princeton, Solco, and PrinJohnson		See Title Cell	P - 10.8.19	PrinJohnson's Facebook Identifies Du as its CEO
Baohua	Chen	Chairman and General Manager		ZHP and PrinJohnson	P - 11.12.19	His senior role in the investigation of the Valsartan contamination. PrinJohnson's Facebook identifies him as its CEO.
Analytical						
Xie	Chaojun		Analyst	ZHP	P - 10.8.19	
Min	Li	VP	Analytical Operations	ZHP	D - 9.23.19	
Minfa	Wang	VP	Analytical Operations	ZHP/Princeton	P - 10.8.19	
Qing	Wang			ZHP	P - 10.8.19	
Dachuan	Zhao	VP	Analytical, Shanghai R&D Center	ZHP	P - 11.12.19	Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Xin	Geng	Post Doctoral Fellow and Research Scientist		Huahai US	P - 11.12.19	"Expertise in various purification techniques including chromatography, recrystallization, and distillation" -Linkedin
Jack	Guan	Senior Director Analytical Operations		Princeton	P - 11.12.19	"A pharmaceutical professional with strong expertise in analytical R&D, Quality Control, Pre-formulation, Quality Assurance, Compliance and Regulatory Affairs. Proven track records of leading operations and activities in analytical R&D, quality units, health authority inspections, and project management." -Linkedin
XiaXia	Zhang	Analytical and Testing Department Manager	Chuannan Branch Analytical Center	ZHP	P - 11.22.19	Org Chart
Jun	Wang	Finished Dose Gase Stage Team	Chuannan Branch Analytical Center	ZHP	P - 11.22.19	Org Chart
Chun	Yang	Finished Dose Liquid Phase Team	Chuannan Branch Analytical Center	ZHP	P - 11.22.19	Org Chart

Guang	Zheng	Raw Material Central Control Instrument Team	Chuannan Branch Analytical Center	ZHP	P - 11.22.19	Org Chart
XianLiang	Zhang	Raw Material Central Control Physico-Chemical Team	Chuannan Branch Analytical Center	ZHP	P - 11.22.19	Org Chart
Yun	Jin		Chuannan Branch Analytical Center	ZHP	P - 11.22.19	Org Chart
Quality						
Wei	Cheng	VP	API Quality Assurance	ZHP	P - 10.8.19	
Remonda	Gergis	VP	Quality Assurance	Prinston	P - 10.8.19	
Zheng	Youqing	Deputy Manager	Quality Assurance	ZHP	P - 10.8.19	
Jucal	Ge	Director	Quality Assurance (API Division)	ZHP	D - 9.23.19	
Yuelin	Hu	Assistant Director	Quality Assurance (API Division)	ZHP	D - 10.7.19	
Ziqiang	Gu	Independent Consultant		ZHP and Prinston	P - 10.8.19	
Xiaohong	Zhao	Director	Quality Assurance (Chuannan Site)	ZHP	P - 10.8.19	
Hongliang	Wang		Quality	ZHP	P - 11.12.19	Prepared Method Validation Report of Valsartan PRINSTON00031401
Zhen	Ye		Quality	ZHP	P - 11.12.19	Reviewed part of Method Validation Report of Valsartan PRINSTON00031402
Baozhen	Chen	Director	Corporate Quality Assurance	ZHP	P - 11.12.19	Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Cunxiao	Ye	Vice President	Quality Assurance, Headquarters	ZHP	P - 11.12.19	Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Caifeng	Zhao	Manager	Quality Assurance	ZHP	P - 11.12.19	Prepared Deviation Investigation Report of Valsartan TEA Process V1, 2, & 3 PRINSTON0073443, 0075797, 0076100

Dongqin	Wang	Assistant Director	Quality Assurance at Chuannan Site East Zone	ZHP	P - 11.12.19	Reviewed and signed off on Deviation Investigation Report of Valsartan TEA Process V1, 2, & 3 PRINSTON0073443, 0075797, 0076100; attended 5.19.17 meeting after the FDA inspection PRINSTON0074159
Zhizhang	Ding	Assistant Manager	Formulation Quality Assurance	ZHP	P - 11.12.19	Reviewed and approved Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384
Y.F.	Chen	Senior Supervisor	API Quality Assurance	ZHP	P - 11.12.19	Reviewed and approved Validation Report of LC-MS Method for NDBA in Losartan Potassium PRINSTON0074642; ; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712
Xiong	Fei	Analyst	Quality Control	ZHP	P - 10.8.19	
Hu	Guangping	Director	Quality Control	ZHP	P - 10.8.19	
Huang	Rui	Director	Quality Control	ZHP	P - 10.8.19	
Minli	Zhang	Director	Finished Dose Quality Assurance and Quality Control	ZHP	D - 10.16.19	
Qiangming	Li	Director	Quality Control (API Division)	ZHP	D - 9.23.19	
Zie	Chaojun	Analyst	Quality Control	ZHP	P - 10.8.19	
Quang	Zhou	Analyst	Quality Research	ZHP	D - 10.23.19	
Ying	Xiong	Supervisor	Quality Research	ZHP	D - 10.23.19	
Fong E.	Zhuong	Associate Manager	Quality Research	ZHP	Discussed but not agreed to on 10.23.19	Org Chart
Dan Ping	Cai	Technical Assistant Director	Quality Research	ZHP	Discussed but not agreed to on 10.23.19	Org Chart
Yuanyan	Chen	Supervisor	Quality Research	ZHP	Discussed but not agreed to on 10.23.19	Org Chart
Yinhua	Tang	Assistant Director/Manager	Quality Control	ZHP	P - 11.12.19	Reviewed and signed off on Deviation Investigation Reports of Valsartan TEA Process PRINSTON0073443, etc.; attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Fei	Shang	QP	Quality VP	ZHP	P - 11.12.19	Reviewed and approved the third version of the Deviation Investigation into the TEA process PRINSTON0076100

Yun	Jin	Supervisor	Chuannan Quality Control	ZHP	P - 11.12.19	Drafted Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; draft Chiral Purity Analytical Method Validation Protocol for TDCI Compound PRINSTON00077405
Tian	Zhang	Analyst	Chuannan Q Control	ZHP	P - 11.12.19	Reviewed and signed off on Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; reviewed and signed off on Chiral Purity Analytical Method Validation Protocol for TDCI Compound PRINSTON00077405
Xianhua	Zhang	Deputy Director	Chuannan Quality Control	ZHP	P - 11.12.19	Reviewed and signed off on Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; reviewed and signed off on Chiral Purity Analytical Method Validation Protocol for TDCI Compound PRINSTON00077405
Yuping	Chen	Deputy Manager	Formulation Quality Control	ZHP	P - 11.12.19	Author of Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384
Xiaoling	Li	Manager	Formulation Quality Control	ZHP	P - 11.12.19	Reviewed and signed off on Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384
Qiang	Zhuo	Analyst	API Quality Research	ZHP	P - 11.12.19	Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326
Tong	Wu	Analyst	API Quality Research	ZHP	P - 11.12.19	Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326

Tan	Xiao	Senior Supervisor	API Quality Research	ZHP	P - 11.12.19	Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326; reviewed and approved Validation report of the LC-MS method for NDBA in Losartan Potassium PRINSTON0074642; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712
Wenbin	Chen	Analysis Director	API Quality Research	ZHP	P - 11.12.19	Reviewed and signed off on Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326; ; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712
Nan	Tong	Senior Supervisor	API Quality Research	ZHP	P - 11.12.19	Approved the cGMP compliance for its intended use of Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326
Wenping	Hu	Team Leader	Quality Research	ZHP	P - 11.12.19	Reviewed data in Hydrochlorothiazide Residual Solvent Method Validation Report PRINSTON00064288; Reviewed Comparison of Valsartan USP Method and In-house Method for Integrity and Correctness PRINSTON00064389
Wenquan	Zhu	Director	API Quality Research	ZHP	D- 10.16.19	
X. G.	Liu	Quality Researcher	API Quality Research	ZHP	P - 11.12.19	Drafted Validation report of the LC-MS method for NDBA in Losartan Potassium PRINSTON0074642
Y.Y.	He	Quality Researcher	API Quality Research	ZHP	P - 11.12.19	Drafted Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712
Ye	Jenson		QP	ZHP	P - 11.12.19	Approved the Deviation Investigation Reports of Valsartan TEA Process PRINSTON0073443, etc.
Jieyun	Wang	Director	Quality Assurance	ZHP	P - 11.22.19	PRINSTON00077850
Ting	Sung	Manager	Quality Control	ZHP	P - 11.22.19	Org Chart

Jian	Ye	Deputy Manager, Group I	Quality Control	ZHP	P - 11.22.19	Org Chart
Houming	Zhou	General Detection, Technical Deputy Director	API Quality Study/Research Department	ZHP	P - 11.22.19	Org Chart
Xiao	Yu	Associate Director	API Quality Study/Research Department	ZHP	P - 11.22.19	Org Chart
Yang	Han	Supervisor	Quality Research	ZHP	P - 11.22.19	Org Chart
Chaohua	Bao	Supervisor	API QR	ZHP	P - 11.22.19	Prepared Comparison of Valsartan USP Method and In-house Method PRINSTON00064389
Manufacturing						
Xiamong	Liu	Head	Technical for Finished Dose	ZHP	D - 10.16.19	
Congsheng	Jin	Valsartan Workshop Director		ZHP	P - 11.12.19	Identified as the person “responsible for production of Valsartan”
Yongjun	Jin	Factor Assistant Director	Manufacturing	ZHP	P - 11.12.19	Described as a “professional engineer,” and “has a wide experience at production technology management and is responsible for the technological development of all bulk drugs”
Dong	Peng	Director	Technical Department	ZHP	D - 9.23.19	
Peng	Wang	Senior Director	API Manufacturing	ZHP	D - 9.23.19	
Youhu	Wang	Technology Leader		ZHP	P - 11.12.19	“Is responsible for Valsartan”
Jiangzhong	Yu	API and Intermediate Plant Manager	Manufacturing	ZHP	P - 11.12.19	Responsible for all bulk drugs (including intermediates) at ZHP
Wenling	Zhang	Director Assistant	Technical, API Chuannan site West Zone (counterpart to Peng Dong)	ZHP	P - 11.12.19	Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Lijin	Jiang	VP	API Operation/Facility Director, API Chuannan Site	ZHP	P - 11.12.19	Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Zhengjun	Jia	Deputy Plant Director	Engineering and Maintenance, API Chuannan site East Zone	ZHP	P - 11.12.19	Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158

Junhui	Zuo	Deputy Plant Director	Engineering and Maintenance, API Chuannan site West Zone	ZHP	P - 11.12.19	Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158
Wei	Chen	Deputy Director	Production Department	ZHP	P - 11.12.19	Reviewed and approved Deviation Investigation Reports regarding the TEA Process PRINSTON0073443, 0075797, 0076100
Lina	Wu	Senior Supervisor	Formulation Technology at ZHP	ZHP	P - 11.12.19	Author of Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384
Xiaoming	Liu	Director	Formulation Technology at ZHP	ZHP	P - 11.12.19	Reviewed and signed off on Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384
Eric Wen-Chien	Tsai, PhD	General Manager		Prinston and Prinbury BioPharm	P - 11.12.19	Authorized signatory and sponsor or Quality Assurance Authentification of Valsartan. PRINSTON00029811. "Eric joined Prinbury BioPharm as General Manager in 2009, wholly owned subsidiary of Prinston, a Research and Development center located in Shanghai China. In this role he leads the R&D efforts has been making significant contribution to Prinston pipeline growth. Eric came to the company with strong technical expertise and management skills." -Prinston Website
Pieter	Groenewoud	Executive Director	Technology	ZHP	P - 11.12.19	Reviewed Master Packaging Record Approval PRINSTON00021688
Chunmin	Xu	Vice President		ZHP	P - 11.22.19	PRINSTON00070584, 79392
Hu	Zhou	Factory Director		ZHP	P - 11.22.19	PRINSTON00070586
Ruqi	Zhou	Factory Assistant Director		ZHP	P - 11.22.19	PRINSTON00070587, 79392
Kaai	Yang	Technical Manager		ZHP	P - 11.22.19	PRINSTON00070587, 79392
Ruping	Ren	Auxiliary Workshop Director		ZHP	P - 11.22.19	PRINSTON00077851
Meng	Yanhua	General Manager	Chuannan Product Technical Center	ZHP	P - 11.22.19	Org Chart

Yan	Fengfeng	Director of Tech	Chuannan Product Technical Center	ZHP	P - 11.22.19	Org Chart
Liang	Zunjun	Associate Director	Chuannan Product Technical Center	ZHP	P - 11.22.19	Org Chart
Hu	Zhichen	Manager	Chuannan Product Technical Center	ZHP	P - 11.22.19	Org Chart
Zhan	Xiauhui	"(Valsartan)"	Chuannan Product Technical Center	ZHP	P - 11.22.19	Org Chart
Xie	Mengmeng	General Supporting Group	Chuannan Product Technical Center	ZHP	P - 11.22.19	Org Chart
Regulatory						
Linhong (Linda)	Lin	Director	Regulatory Affairs Department	ZHP	D - 9.23.19	
Wei	Chen	Translator		ZHP	P - 11.12.19	Translated 08/26/2018 Ltr to the FDA
Zhi	Chen			Huahai US	P - 10.8.19	
Yanfeng (Lucy)	Liu	Deputy Director / Manager	Regulatory Affairs	ZHP	D - 10.7.19	
Lije	Wang	VP	Head of Regulatory Affairs	Prinston	P - 10.8.19	
Ying	Xiong	Supervisor	Regulatory Affairs	ZHP	D 10.16.19	
Quo (Kathy)	Zhang	Senior Manager	Regulatory Affairs	Huahai US	P - 10.8.19	
Xiaodi	Guo	Vice President		Huahai US (linkedin), Prinston (website), and Solco (affidavits of service)	P for Prinston/Huahai US - 10.8.19 / Solco - 11.12.19	He has accepted service as Solco's VP.
Wei (Helen)	Tong	Director	Regulatory Affairs	ZHP and Prinston?	P - 11.12.19	Listed on ANDA Documents
Ting (Ada)	Zhou	Assistant Director	Regulatory Affairs	ZHP	D - 10.7.19	
Louis	Zhao		Regulatory Affairs	Prinston	P - 11.12.19	Linkedin

Guangyu	Luo	Associate (2013-2015), Senior Associate (2015-2016), Specialist (2016-2017), Manager (2017-Present)		Prinston	P - 11.12.19	"Regulatory Affairs, mainly on regulatory submissions (from draft to e-CTD compilation), pharmacovigilance (AE handling and submission) and generic labeling (content, artwork and SPL)." -Linkedin
Jenny	Lu	Senior Associate	Regulatory Affairs	Prinston	P - 11.12.19	Linkedin
Yuding	Zhao	Director	Finished Dose RA	ZHP	D - 10.23.19	
Yiming	Tang				P - 11.22.19	Contact Person for ZHP's U.S. Agent PRINSTON0076915
Sun	Dengxue	Manager	API R&D, Regulation Affairs	ZHP	P - 11.22.19	Org Chart
Lin	Jie	Deputy Manager	API Patent, Regulation Affairs	ZHP	P - 11.22.19	Org Chart
Procurement						
Min	Hu		Purchasing	ZHP	D - 10.16.19	
Weiwei	Xu		Purchasing	ZHP	D - 10.16.19	
Min	Xu		Purchasing	ZHP	D - 10.16.19	
Min	Xang		Procurement	ZHP	D - 10.16.19	
Zheng	Gaozhe		Purchasing	ZHP	D - 10.16.19	Was a person who was responsible for procuring solvents
API Sales						
Minda	Cai	Former VP	API Sales	ZHP	D - 10.16.19	
Jie	Wang	VP	Business Development	ZHP	D - 9.23.19	
Sheng	Zhong	Director	Business Development	ZHP	D - 10.16.19	
Wei	Chang	Translator	Business Development, API Sales	ZHP	D - 10.23.19	
Hongchao	Li	Manager	Business Development	ZHP	D - 10.16.19	
Xu	Mi		Business Development, API Sales	ZHP	D - 10.16.19	
Wang	Yihua	Vice President	Sales	ZHP	P - 11.22.19	Org Chart
Ki	Qing	"Brand Customer"	Sales	ZHP	P - 11.22.19	Org Chart
Tong	Zengyuan	"Customer Service"	Sales	ZHP	P - 11.22.19	Org Chart
Tang	Fengyang	Manager Assistant	Sales	ZHP	P - 11.25.19	Org Chart
Wang	Lina	Manager Assistant	Sales	ZHP	P - 11.25.19	Org Chart

Li	Qing	Director of Original Drug, Key Account Business Department	Sales	ZHP	P - 11.25.19	Org Chart
Xu	Baoxi	Director Assistant	Sales	ZHP	P - 11.25.19	Org Chart
Wu	Yuehua	Manager of Document Group	Sales	ZHP	P - 11.25.19	Org Chart
Wang	Haiqun	Assistant Manager of Office Work Group	Sales	ZHP	P - 11.25.19	Org Chart
Other Sales						
John	Iozzia	Director	Sales	Huahai US	D - 10.16.19	
Chris	Keith	Director	Sales	Solco/Princeton at some point as VP	D - 10.22.19 for Solco / Princeton - 11.12.19	Solco's Website
Lesley	Zhu	SVP, Business Development & Portfolio	Sales	Princeton	P - 10.8.19	
Hai	Wang	VP, President, President		Huahai US (linkedin), Princeton (website), & Solco (website), respectively	P for Solco - 10.8.19	
Min	Hu	Manager of Business Development and Senior Director of Business Development		Huahai US (2007-2012) and Princeton (2012-Present), respectively	P - 11.12.19	Linkedin
David	Ayres	Vice President	Sales	Solco	P - 11.12.19	Solco's Website
Xin (Will)	He	Scientist (2012-2016), Manager (2019-Present)		Princeton	P - 11.12.19	"Working at formulation position of Product Development Department." -Linkedin
Peng	Shang	Senior Associate of Business Development/ Supply Chain		Princeton	P - 11.12.19	Linkedin
Matthew	Arnold	National Account Manager from 2016-2019		Solco	P - 11.12.19	Linkedin and Author of Only Solco-stamped document
Syncores						
Eric	Gu	Manager		Shanghai Syncores	P - 10.8.19	

Derek	Zhang, PhD			Alavanda Regulatory & Drug Development Consulting, Inc. (Regulatory Consultant for Prinston Pharmaceutica l Inc.)	D - 10.23.19	
Dylan	Yao, Ph.D.	Chief Scientific Officer & Senior Vice President		Jonn Laboratories Inc. (Consultant for Prinston Pharmaceutica l Inc.)	D - 10.23.19	
Charles	Wang	VP of Drug Safety and DMPK		Consultant from InnoCare Pharma, Inc. for ZHP	D 10.23.19	
Douglas	Campbell	Consultant		ZHP	P - 11.22.19	Email PRINSTON00070408